Rhythm Pharmaceuticals, Inc.
IMCIVREE
acquired hypothalamic obesity
Resolved
110days ago
Approval decision · Mar 19, 2026
What's at stake
A final FDA approval decision on IMCIVREE for acquired hypothalamic obesity is expected Mar 19, 2026.
Primary source
· SEC 8-K
verified 14h ago
“IMCIVREE was approved by the FDA for the treatment of acquired HO;”